JP2014518624A - ニューログラニン診断キットのためのアッセイ試薬 - Google Patents

ニューログラニン診断キットのためのアッセイ試薬 Download PDF

Info

Publication number
JP2014518624A
JP2014518624A JP2014510535A JP2014510535A JP2014518624A JP 2014518624 A JP2014518624 A JP 2014518624A JP 2014510535 A JP2014510535 A JP 2014510535A JP 2014510535 A JP2014510535 A JP 2014510535A JP 2014518624 A JP2014518624 A JP 2014518624A
Authority
JP
Japan
Prior art keywords
fragment
neurogranin
antibody
aptamer
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518624A5 (https=
Inventor
アレン デイル エヴェレット
ジュン ヤン
ゾンミン フー
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2014518624A publication Critical patent/JP2014518624A/ja
Publication of JP2014518624A5 publication Critical patent/JP2014518624A5/ja
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2014510535A 2011-05-12 2012-05-14 ニューログラニン診断キットのためのアッセイ試薬 Pending JP2014518624A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485375P 2011-05-12 2011-05-12
US61/485,375 2011-05-12
PCT/US2012/037774 WO2012155134A2 (en) 2011-05-12 2012-05-14 Assay reagents for a neurogranin diagnostic kit

Publications (2)

Publication Number Publication Date
JP2014518624A true JP2014518624A (ja) 2014-08-07
JP2014518624A5 JP2014518624A5 (https=) 2015-07-02

Family

ID=47140053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510535A Pending JP2014518624A (ja) 2011-05-12 2012-05-14 ニューログラニン診断キットのためのアッセイ試薬

Country Status (4)

Country Link
US (3) US20140141458A1 (https=)
EP (1) EP2707389B1 (https=)
JP (1) JP2014518624A (https=)
WO (1) WO2012155134A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529527A (ja) * 2014-08-26 2017-10-05 イマビオテクImabiotech 質量分析イメージングによってサンプルを特徴づける方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2628013B1 (en) * 2010-10-14 2019-06-12 The Johns Hopkins University Biomarkers of brain injury
JP2014518624A (ja) 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー ニューログラニン診断キットのためのアッセイ試薬
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2014193800A2 (en) * 2013-05-28 2014-12-04 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
EP3022322A4 (en) * 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
EP3242134A1 (en) 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
WO2018217792A1 (en) * 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504032A (ja) * 2004-06-25 2008-02-14 ワシントン・ユニバーシティ 脳損傷に対するマーカー

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
US5866434A (en) 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
EP0821726B1 (en) 1995-03-10 2014-05-07 Meso Scale Technologies, LLC. Multi-array, multi-specific electrochemiluminescence testing
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6319670B1 (en) 1995-05-09 2001-11-20 Meso Scale Technology Llp Methods and apparatus for improved luminescence assays using microparticles
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
WO2002024867A2 (en) 2000-09-22 2002-03-28 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
WO2003001889A2 (en) 2001-06-29 2003-01-09 Meso Scale Technologies, Llc. Assay plates reader systems and methods for luminescence test measurements
AU2002365119A1 (en) 2001-07-30 2003-09-04 Meso Scale Technologies, Llc. Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
JP2005522669A (ja) 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
WO2003023360A2 (en) 2001-09-10 2003-03-20 Meso Scale Technologies, Llc Methods and apparatus for conducting multiple measurements on a sample
AU2002324947B2 (en) 2001-09-10 2007-11-15 Meso Scale Technologies, Llc. Assay buffer, compositions containing the same, and methods of using the same
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
JP4781628B2 (ja) 2001-12-05 2011-09-28 センス プロテオミック リミテッド 対立遺伝子改変体のためのタンパク質アレイおよびその使用
WO2003102015A2 (en) * 2002-05-29 2003-12-11 University Of Florida Method and apparatus for detecting and monitoring peptides, and peptides identified therewith
US7036946B1 (en) 2002-09-13 2006-05-02 Rockwell Collins, Inc. LCD backlight with UV light-emitting diodes and planar reactive element
EP1583950B1 (en) 2002-12-26 2017-04-05 Meso Scale Technologies, LLC. Assay cartridges and methods of using the same
US7981362B2 (en) 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
EP2207033B1 (en) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US7776583B2 (en) 2004-06-03 2010-08-17 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
ES2443042T3 (es) 2006-10-16 2014-02-17 Bayer Intellectual Property Gmbh LTBP2 como biomarcador, diana terapéutica y diagnóstica
EP2015196A1 (en) 2007-06-28 2009-01-14 Siemens Aktiengesellschaft Programmer interface for manufacturing execution system
EP2294425B1 (en) * 2008-05-23 2013-05-22 The Johns Hopkins University Biomarkers for myocardial ischemia
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
JP2014518624A (ja) 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー ニューログラニン診断キットのためのアッセイ試薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504032A (ja) * 2004-06-25 2008-02-14 ワシントン・ユニバーシティ 脳損傷に対するマーカー

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6016011920; Molecular Brain Research, 1994, vol.27, pp.323-328 *
JPN6016011922; Brain Research, 1995, vol.685, pp.143-153 *
JPN6016011925; Developmental Neurobiology, 2009, vol.69, no.2-3, pp.124-140 *
JPN6016011927; Brain Research, 2007, vol.1143, pp.78-82 *
JPN6016011932; Clinical Chemistry, 1999, vol.45, no.9, pp.1628-1650 *
JPN6016011936; Brain Research, 2010, vol.1362, pp.13-22 *
JPN6016011939; Technological Innovation and Resources, Epub 2011 Feb 27. vol.10, no.6, M110.006593 *
JPN6016011941; AB SCIEX, 2010 [検索日:2016年3月17日] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529527A (ja) * 2014-08-26 2017-10-05 イマビオテクImabiotech 質量分析イメージングによってサンプルを特徴づける方法

Also Published As

Publication number Publication date
US10215764B2 (en) 2019-02-26
EP2707389A2 (en) 2014-03-19
WO2012155134A3 (en) 2013-06-13
US20170315138A1 (en) 2017-11-02
EP2707389B1 (en) 2019-10-30
WO2012155134A2 (en) 2012-11-15
EP2707389A4 (en) 2015-08-12
US9709578B2 (en) 2017-07-18
US20170038397A1 (en) 2017-02-09
US20140141458A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
US10215764B2 (en) Assay reagents for a neurogranin diagnostic kit
US10914749B2 (en) Biomarkers of cognitive dysfunction
JP2021192036A (ja) Als関連ジアミノ酸リピート含有タンパク質
CN112567246B (zh) 治疗脊髓性肌萎缩症的方法
CA2600168A1 (en) Markers of renal transplant rejection and renal damage
CN111699391A (zh) 用于诊断和评估创伤性脑损伤的新型生物标志物和方法
CN106461681B (zh) 用于诊断血管疾病的生物标志物及其用途
JP2010014689A (ja) プロテオミクス解析を用いたメラノーママーカーの同定
AU2019255622B2 (en) Compositions and methods for treating cardiovascular disease in selected patients
TWI465720B (zh) 預測神經發育、神經的或神經精神性病症治療之臨床效益之方法
EP2795337B1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
EP2631656B1 (en) Marker for amyotrophic lateral sclerosis, and use thereof
KR102193393B1 (ko) 신부전 환자에서 신장 이식 거부반응 및 심혈관계 합병증의 진단 또는 예측을 위한 마커로써 엔도칸 및 이의 용도
EP4619416A1 (en) Methods to detect csf mtbr-tau and uses thereof
KR20260051980A (ko) 혈소판 FcγRIIa에 대한 항체 및 관련된 사용 방법
EP4572792A2 (en) ANTIBODIES FOR PLATELET FCgammaRIIA AND RELATED METHODS OF USE
CA3213085A1 (en) Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
HK40130133A (zh) 检测csf mtbr-tau的方法及其用途
EA050606B1 (ru) Способы лечения спинальной мышечной атрофии
NZ620075B2 (en) A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161128